Insider Selling: Nautilus Biotechnology, Inc. (NASDAQ:NAUT) VP Sells $99,750.00 in Stock

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) VP Mary E. Godwin sold 35,000 shares of the company’s stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $2.85, for a total transaction of $99,750.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Nautilus Biotechnology Stock Up 2.7 %

Shares of NASDAQ NAUT opened at $3.08 on Friday. The firm has a 50-day simple moving average of $2.59 and a 200-day simple moving average of $2.59. The stock has a market capitalization of $385.82 million, a price-to-earnings ratio of -5.60 and a beta of 1.20. Nautilus Biotechnology, Inc. has a 52 week low of $2.19 and a 52 week high of $3.62.

Nautilus Biotechnology (NASDAQ:NAUT) last released its quarterly earnings data on Tuesday, July 30th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.02. During the same quarter last year, the company posted ($0.13) earnings per share. As a group, equities research analysts expect that Nautilus Biotechnology, Inc. will post -0.65 EPS for the current year.

Wall Street Analyst Weigh In

NAUT has been the subject of a number of research analyst reports. Jefferies Financial Group initiated coverage on Nautilus Biotechnology in a report on Monday, June 3rd. They set a “hold” rating and a $3.00 target price for the company. Guggenheim initiated coverage on Nautilus Biotechnology in a research report on Thursday, June 27th. They set a “buy” rating and a $6.00 price target for the company.

Institutional Investors Weigh In On Nautilus Biotechnology

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Perceptive Advisors LLC grew its holdings in Nautilus Biotechnology by 38.2% in the 4th quarter. Perceptive Advisors LLC now owns 12,594,211 shares of the company’s stock valued at $37,657,000 after buying an additional 3,483,060 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Nautilus Biotechnology by 19.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 574,844 shares of the company’s stock valued at $1,345,000 after acquiring an additional 94,908 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Nautilus Biotechnology by 1.0% in the first quarter. Vanguard Group Inc. now owns 2,859,402 shares of the company’s stock valued at $8,407,000 after purchasing an additional 29,604 shares during the period. Clarius Group LLC increased its position in Nautilus Biotechnology by 2.7% during the second quarter. Clarius Group LLC now owns 636,532 shares of the company’s stock worth $1,489,000 after purchasing an additional 16,661 shares during the last quarter. Finally, Renaissance Technologies LLC raised its stake in Nautilus Biotechnology by 11.2% during the second quarter. Renaissance Technologies LLC now owns 140,100 shares of the company’s stock worth $328,000 after purchasing an additional 14,100 shares during the period. Institutional investors and hedge funds own 50.71% of the company’s stock.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.